ClinicalTrials.gov

History of Changes for Study: NCT04969835
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Latest version (submitted July 21, 2021) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 July 20, 2021 None (earliest Version on record)
2 July 21, 2021 Recruitment Status, Study Status and Contacts/Locations
Comparison Format:

Scroll up to access the controls

Changes (Merged) for Study: NCT04969835
July 20, 2021 (v1) -- July 21, 2021 (v2)

Changes in: Study Status and Contacts/Locations

Open or close this module Study Identification
Unique Protocol ID: ALS-6000-101
Brief Title: A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Official Title: A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours
Secondary IDs:
Open or close this module Study Status
Record Verification: June July 2021
Overall Status: Not yet Recruiting
Study Start: July 12 16, 2021
Primary Completion: May 31, 2023 [Anticipated]
Study Completion: June 30, 2023 [Anticipated]
First Submitted: June 22, 2021
First Submitted that
Met QC Criteria:
July 20, 2021
First Posted: July 21, 2021 [Actual]
Last Update Submitted that
Met QC Criteria:
July 20 21, 2021
Last Update Posted: July 21 22, 2021 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Avacta Life Sciences Ltd
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with locally advanced and/or metastatic solid tumours. In Phase Ia, using a 3+3 design, escalating doses of AVA6000 will be administered to patients with a range of solid tumour types to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). In Phase 1b, the selected RP2D dose will be assessed in one to three tumour types.
Detailed Description:

This study is a first-in-human (FIH), Phase 1, open-label, multicentre, dose-escalation study investigating AVA6000 monotherapy administered intravenously (IV) in patients with locally advanced (unresectable) and/or metastatic solid tumours.

The study will be conducted in two parts: Phase 1a (Dose Escalation) and Phase 1b (Dose Expansion):

Phase 1a (Dose Escalation): The dose-escalation phase is designed to evaluate the safety, tolerability and MTD and/or RP2D of AVA6000, administered as monotherapy

Phase 1b (Dose Expansion): The dose-expansion phase will comprise 1 to 3 expansion arms in specific tumour types to evaluate the safety and tolerability of AVA6000 at the MTD or RP2D when administered as monotherapy. The tumour types to be explored in Phase 1b, will be determined based on evaluation of the Phase 1a data and the protocol will be amended accordingly.

Open or close this module Conditions
Conditions: Pancreatic Cancer
Colorectal Cancer
Non-small Cell Lung Cancer
Breast Cancer
Head and Neck Cancer
Soft Tissue Sarcoma
Ovarian Cancer
Bladder Cancer
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 1
Interventional Study Model: Sequential Assignment
This Phase I study will follow a standard 3+3 design in Part 1a to determine the maximum tolerated dose (MTD) and/or recommended dose of AVA6000, given as an intravenous infusion, to be used in Part 1b in the dose-expansion phase in up to 3 tumour types.
Number of Arms: 2
Masking: None (Open Label)
Allocation: Non-Randomized
Enrollment: 80 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: AVA6000 Phase 1a
Patients in Phase Ia will receive escalating doses of AVA6000 following a 3+3 design, commencing with a starting dose of 80mg/m2, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first.
Drug: AVA6000
AVA6000 is a FAP-activated prodrug of doxorubicin. AVA6000 will be administered via IV infusion every 3 weeks. Dosing will occur based on the calculated patient's BSA on the day of dosing.
Experimental: AVA6000 Phase 1b
Patients in Phase Ib will receive the RP2D dose of AVA6000, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first. One to three tumour types will be selected based on the assessment of Phase 1a data.
Drug: AVA6000
AVA6000 is a FAP-activated prodrug of doxorubicin. AVA6000 will be administered via IV infusion every 3 weeks. Dosing will occur based on the calculated patient's BSA on the day of dosing.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Number of participants with dose-limiting toxicities (DLTs)
[ Time Frame: Cycle 1, 21 days ]

2. Percentage of patients with Dose-Limiting toxicities (DLTs) of AVA6000 during the DLT period
[ Time Frame: Cycle 1, 21 days ]

3. Maximum-tolerated dose (MTD) or Recommended Phase 2 dose (RP2D)
[ Time Frame: Cycle 1, 21 days ]

4. Percentage of patients with Adverse Events (AEs) at RP2D AVA6000 dose level in tumour-specific expansion arms.
[ Time Frame: Cycle 1, 21 days ]

Secondary Outcome Measures:
1. Maximum drug concentration (Cmax) of AVA6000 & Doxorubicin
[ Time Frame: Cycle 1 and Cycle 2, 0-72 hours post dose (Dose Escalation) ]

Cmax (maximum plasma concentration) of AVA6000 and Doxorubicin after administration after Cycle 1 and 2 for 72 hours post-dose.
2. Area under the concentration versus time curve (AUC) of AVA6000 & Doxorubicin
[ Time Frame: Cycle 1 and Cycle 2, 0-72 hours post dose (Dose Escalation) ]

AUC (Area under the concentration versus time curve) of AVA6000 and Doxorubicin after administration after Cycle 1 and 2 for 72 hours post-dose.
3. Elimination half-life (t1/2) of AVA6000 & Doxorubicin
[ Time Frame: Cycle 1 and Cycle 2, 0-72 hours post dose (Dose Escalation) ]

t1/2 (Elimination half-life) of AVA6000 and Doxorubicin after administration after Cycle 1 and 2 for 72 hours post-dose.
4. Renal clearance (CLr) of AVA6000 & Doxorubicin
[ Time Frame: Cycle 1 and Cycle 2, 0-72 hours post dose (Dose Escalation) ]

CLr (Renal clearance) of AVA6000 and Doxorubicin after administration after Cycle 1 and 2 for 72 hours post-dose.
5. Objective response rate (ORR)
[ Time Frame: Up to one year ]

ORR is defined as the proportion of patients achieving a best overall response of confirmed partial responses (PR) or complete response (CR), per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
6. Duration of Response (DoR)
[ Time Frame: Up to one year ]

DoR is defined as the duration of time from date of first response to date of disease progression, as per RECIST v1.1
7. Progression-free-survival (PFS)
[ Time Frame: Up to one year ]

PFS is defined as the time from the date of the first dose to the date of the first documentation of confirmed disease progression or death, whichever occurs first, as per RECIST v1.1
8. Overall survival (OS)
[ Time Frame: Up to one year ]

Overall survival (OS), defined as the date of first dose) to the occurrence of death from any cause
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Key Inclusion Criteria:

  1. Willing and able to give written informed consent
  2. Male or female patients, ≥18 years of age
  3. Histological or cytological confirmation of a locally advanced (unresectable) and/or metastatic pancreatic, CRC, NSCLC, SCCHN, ovarian, breast, soft tissue sarcoma and bladder cancer, who have either relapsed or progressed on SoC treatment or are intolerant or nonamenable to SoC treatment
  4. In Phase 1b part of the study only: At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥10mm in the largest diameter (except lymph nodes, which must have a short axis ≥15 mm) with CT or MRI scan and that is suitable for accurate repeated measurements.
  5. Life expectancy of greater than 12 weeks, in the opinion of the investigator
  6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
  7. Recovered from all acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure (must have resolved to CTCAE grade ≤1 or returned to baseline, except alopecia and peripheral neuropathy, which can be up to CTCAE grade 2)
  8. Adequate haematological function (applies only to patients not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose):
    1. Neutrophil count of ≥1.5× 10^9 cells/L
    2. Haemoglobin ≥9g/dL (with or without transfusion support)
    3. Platelet count of ≥75,000/μL (without transfusion within 2 weeks prior to Cycle 1, Day 1)
    4. International normalised ratio (INR) and activated partial thromboplastin time (aPTT) ≤1.5 times the upper limit of normal (ULN)
  9. Adequate liver function:
    1. Total bilirubin ≤1.5 × ULN (in patients with Gilbert's Syndrome, <3 × ULN is allowed)
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (in patients with liver metastases, <5 × ULN is allowed)
    3. Alkaline phosphatase (ALP) <5 × ULN (patients with documented liver or bone metastases only)
  10. Adequate renal function:

    a. Serum creatinine ≤1.5 × ULN (in patients for whom, in the Investigator's judgment, serum creatinine levels do not adequately reflect renal function, creatinine clearance by Cockcroft-Gale formula ≥ 50 mL/min may be used)

  11. Women of childbearing potential (WOCBP) and women who have ≤ 2 years amenorrhea after start of menopause: has a negative serum pregnancy test within 7 days prior to Cycle 1, Day 1
  12. Contraception requirements:
    1. Female patients of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method (Pearl Index failure rate <1% per year) during the treatment period and for at least 6 months after the last dose of study drug
    2. Male patients with female partners of childbearing potential must agree to use 2 acceptable methods of contraception (Pearl Index failure rate <1% per year), including a barrier method (with or without spermicide) during the treatment period and for at least 6 months after the last dose of study drug

Key Exclusion Criteria:

  1. Received trastuzumab within 7 months of the planned Cycle 1, Day 1 AVA6000 infusion
  2. Received a prior total cumulative anthracycline dose of >350mg/m^2 doxorubicin hydrochloride (or equivalent anthracycline dose)
  3. Clinically significant or untreated central nervous system (CNS) metastases requiring treatment, as determined by the Investigator.
  4. Has leptomeningeal disease
  5. Any history of an active (requiring treatment) other malignancy (except any in-situ carcinoma, non-melanoma skin carcinoma and early prostate cancer with a normal PSA) within 2 years of study entry
  6. Has a significant, uncontrolled, concomitant disease that could affect compliance with the protocol
  7. Has uncontrolled hypertension (systolic blood pressure [SBP] >150 mmHg and/or diastolic [DBP] >100 mm Hg), unstable angina, congestive heart failure (New York Heart Association (NYHA) Class >II), left ventricular ejection fraction (LVEF) <55% or the low limit of institutional normal limit (whichever is lower) by echocardiogram (ECHO), serious cardiac arrhythmia requiring treatment (exceptions include atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months prior to Cycle 1, Day 1; history of uncontrolled cardiovascular disease or high-sensitivity troponin above normal at baseline
  8. Screening baseline mean QTcF interval (Fridericia's) of >470 msec, obtained from 3 electrocardiograms (ECGs). Has any clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval >250msec). Has any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, known family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval, a baseline resting bradycardia <45 beats/min or a baseline resting tachycardia of >100 beats/min
  9. Known uncontrolled HIV infection
  10. Active hepatitis B (HBV) or hepatitis C (HCV) infection:
    1. Positive hepatitis B surface antigen (HBsAG) test at Screening. Patients with a past or resolved HBV infection (defined as having a negative HBsAG test and a positive antibody to hepatitis B core antigen [antiHBc] antibody test) are eligible.
    2. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA
  11. Severe infection(requiring IV treatment)within 21 days prior to Cycle 1, Day 1 including, but not limited to, hospitalisation for complications of infection, bacteraemia, or severe pneumonia
  12. Any other clinically significant active disease, metabolic dysfunction, physical examination finding, clinical laboratory finding, or reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drugin the opinion of the investigator.
  13. Major surgery within 21 days prior to Cycle 1, Day 1 (excluding biopsies) or anticipates the need for major surgery during study treatment
  14. Has dementia or altered mental status that in the opinion of the investigator would preclude providing informed consent
  15. Pregnant or breastfeeding woman
  16. Known hypersensitivity to any of the components of AVA6000 or any excipient related to the product
  17. Received prior investigational therapy (defined as a treatment for which there is no Regulatory Authority-approved indication) within 21 or 42 days of Cycle 1 Day 1, for small molecule and biologic investigational therapies, respectively.
  18. Received any approved anticancer therapy, including chemotherapy or hormonal therapy, within 28 days prior to Cycle 1, Day 1, with the following exceptions:
    1. Hormone-replacement therapy or oral contraceptives
    2. Tyrosine kinase inhibitors (TKIs) that have been discontinued more than 7 days prior to Cycle1, Day 1
  19. Is planned for on study treatment or has received within 21 days prior to Cycle 1, Day 1: St John's Wort, any strong inhibitor or inducer of CYP3A4, CYP2D6, narrow therapeutic index CYP1A2, CYP2B6, or P-glycoprotein (PGP) ̧ or any moderate OATP1B3 inhibitor (will include statins)
  20. Received systemic immunosuppressive medication (for any indication) at doses of >10mg prednisolone (or equivalent) within 28 days prior to Cycle 1, Day 1.
  21. Received radiotherapy within 28 days prior to Cycle 1, Day 1, except for limited field palliative radiotherapy. Patients who have received prior or concomitant radiotherapy to the mediastinal area are also excluded.
Open or close this module Contacts/Locations
Central Contact Person: Avacta Life Sciences
Telephone: +44 (0)1904 21 7070
Email: clinicaltrials@avacta.com
Locations: United Kingdom
The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde
[Not yet recruiting]
Glasgow, United Kingdom, G12 0YN
Contact:Principal Investigator: Professor Jeff Evans
St James's University Hospital, The Leeds Teaching Hospitals NHS Trust
[Not yet recruiting]
Leeds, United Kingdom, LS9 7TF
Contact:Principal Investigator: Professor Chris Twelves
The Royal Marsden, NHS Foundation Trust
[Recruiting]
London, United Kingdom, SM2 5PT
Contact:Principal Investigator: Professor Udai Banerji
The Christie NHS Foundation Trust
[Not yet recruiting]
Manchester, United Kingdom, M20 4BX
Contact:Principal Investigator: Dr Natalie Cook
The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust
[Not yet recruiting]
Newcastle upon Tyne, United Kingdom, NE7 7DN
Contact:Principal Investigator: Professor Ruth Plummer
Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust
[Not yet recruiting]
Sheffield, United Kingdom, S10 2SJ
Contact:Principal Investigator: Dr Robin Young
Open or close this module IPDSharing
Plan to Share IPD: No
Qualified researchers may request access to individual patient-level data through clincialtrials@avacta.com
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services